Neurocrine Biosciences INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Neurocrine Biosciences, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 27, 2026, to vote on director elections, executive compensation, equity plan amendments, and auditor ratification.
NASDAQ
Neurocrine Biosciences has filed a definitive proxy statement with the SEC, outlining information for an upcoming shareholder meeting.
NASDAQ
Neurocrine Biosciences sets date for annual stockholder meeting on May 21, 2025, outlining key proposals including director elections and equity incentive plans.
NASDAQ
Neurocrine Biosciences has filed a definitive proxy statement with the SEC.
NASDAQ
Neurocrine Biosciences is holding its annual meeting on May 22, 2024, to vote on director elections, executive compensation, an equity incentive plan amendment, and auditor ratification.